The Direxion Daily S&P Biotech Bull Shares (NYSE: LABU) lost just over a third of a percent Tuesday, but even with that modest loss, the first triple-leveraged bullish biotechnology exchange traded is one of Direxion's best performing ETFs over the past few days with an April gain of over 12 percent.
Previously beloved biotech ETFs have been beaten up this year. Benchmark funds, such as the SPDR S&P Biotech ETF (NYSE: XBI), the ETF that LABU is the triple-leveraged answer to, lost more than 20 percent in the first quarter. For its part, LABU has lost nearly two-thirds of its value this year and was recently reverse split.
So it's reasonable to say it's going to take more ...
/www.benzinga.com/general/biotech/16/04/7807831/inklings-of-upside-for-a-leveraged-biotech-etf alt=Inklings Of Upside For A Leveraged Biotech ETF>Full story available on Benzinga.com
More...